Is HBsAg Loss an Ideal End-point of Oral Antiviral Therapy in Chronic Hepatitis B Patients?.
10.4166/kjg.2014.63.5.329
- Author:
Keunhee KANG
1
;
Ji Hoon KIM
Author Information
1. Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea. kjhhepar@naver.com
- Publication Type:Brief Communication ; Comment
- MeSH:
Antiviral Agents/*therapeutic use;
Carcinoma, Hepatocellular/*virology;
Female;
Hepatitis B Surface Antigens/*blood;
Hepatitis B, Chronic/*blood/*drug therapy;
Humans;
Liver Neoplasms/*virology;
Male
- From:The Korean Journal of Gastroenterology
2014;63(5):329-332
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
No abstract available.
